Recon: EU in talks to reserve J&J COVID-19 vaccine; Pfizer gene therapy shows sustained effect in hemophilia study

• Drugmakers Have Even Less Reason to Fear Price Reform Now (Bloomberg)
• Gilead to enroll pediatric patients for late-stage remdesivir study (Reuters)
• Pfizer's hemophilia gene therapy shows sustained effect in early-stage study (Reuters) (Endpoints) (Press)
• Trump pushing officials to speed up already-ambitious coronavirus vaccine timeline (Washington Post)
• California attorney general says FTC failed to follow ‘best practices’ in approving AbbVie-Allergan deal (STAT) (Endpoints)
• AbbVie spends $60M, with $805M in biobucks, for Alpine Immune's lupus asset (Fierce) (Endpoints)
• A majority of Americans fear pharma will use Covid-19 as an excuse to raise prices (STAT)
• 'Medicaid best price' changes aimed at value-based gene therapy contracts: CMS (Reuters) (STAT)
• U.S. district court rules for Mylan in MS drug patent battle with Biogen (Reuters) (Fierce) (Endpoints)
• Medtronic partners with Foxconn to boost ventilator production (Reuters)

• Europeans discuss deal to access potential J&J coronavirus vaccine (Financial Times) (Reuters)
• Roche rheumatoid arthritis drug fails to help COVID-19 patients in Italian study (Reuters)
• WHO testing interim data from COVID-19 trial on HIV drugs (Reuters)
• WHO hopes for hundreds of millions of vaccine doses this year, 2 billion next year (Reuters)
• International regulators stress value of safe and effective vaccines (EMA)
• Pandemic reopens wounds on IP rights (Financial Times)
• UK launches world's first ‘subscription-style’ payment model for antibiotics (PharmaTimes)
• Some Covid-19 trial sponsors never posted other study results in an EU database. Will they hide data again? (STAT)
• Chinese vaccine developers have begun to shed some secrecy around Covid-19 candidates. What do we know? (Endpoints)
• Novacyt shares jump after launch of new COVID-19 testing products (Reuters)

• Test maker targeted by FDA says it responded to US concerns (ABC)
• Ginkgo Bioworks CEO on scaling up Covid-19 testing: ‘If we try, we can win’ (CNBC)
• New study casts more doubt on Swedish coronavirus immunity hopes (Reuters)
• UK ditches COVID-19 app model to use Google-Apple system (Reuters)
• Coronavirus (COVID-19) Update: Daily Roundup June 17, 2020 (FDA)

• US FDA’s Oncology Center In The Lockdown: ‘Business As Usual’ (Pink Sheet)
• Cures II Wish List: Reconsidering Accelerated Approval? (Pink Sheet)
• Opinion: It’s Time to Make the FDA Independent (Politico)
• Lilly touts Emgality's ability to reduce migraine patients' overall pain in first look at 'holistic approach' (Fierce)
• Tecentriq passes neoadjuvant breast cancer trial as Roche looks for early start on the next big checkpoint opportunity (Endpoints) (Press)
• Two Bay Area upstarts out to deliver on cell therapy 2.0 join forces on a quest: pursuing a Holy Grail in oncology R&D (Endpoints)
• AbbVie’s Rinvoq passes PhIII AD test; Dicerna races Alnylam; New Sarepta gene & cell collab (Endpoints) (Press)
• Nan Fung Life Sciences antes up $32M to fuel a neuro play as the Hong Kong conglomerate burns through $1.5B mandate (Endpoints)

• ‘Email Me’: FDA Director Says He’ll Cut Through Red Tape To Ensure EUAs Are Assigned Liaison (MedtechInsight)
• US FDA clarifies adverse event reporting requirements for medical devices designated under Emergency Use Authorizations (Emergo)

• The Trump Administration Paid Millions for Test Tubes — and Got Unusable Mini Soda Bottles (ProPublica)
• Shire Wants Jury Trial Over Validity Of Its Genetic Disorder IP (Law360)
• Generic Cos. Ask Fed. Circ. To Deny Amarin's Vascepa Appeal (Law360)
• Biotech Co. Investors' FDA Convo Suit Survives Dismissal Bid (Law360)
• Pharmacies Want Out Of Opioid MDL 'Public Nuisance' Suits (Law360)
• Boehringer Ingelheim Sued For €23M Over Diabetes Drug IP (Law360)